Disease · MONDO_0008170
Comparisons in its trials178
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 178
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Nintedanib vs Placebo: serious adverse events | 379 of 902 | 157 of 450 | 1,352 | NCT01015118 | Trial comparisons |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab vs Placebo With Paclitaxel, Carboplatin and Bevacizumab: deaths from any cause | 272 of 651 | 289 of 650 | 1,301 | NCT03038100 | Trial comparisons |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab vs Placebo With Paclitaxel, Carboplatin and Bevacizumab: serious adverse events | 304 of 642 | 215 of 644 | 1,286 | NCT03038100 | Trial comparisons |
| Niraparib vs Placebo: deaths from any cause | 48 of 484 | 31 of 244 | 728 | NCT02655016 | Trial comparisons |
| Niraparib vs Placebo: serious adverse events | 156 of 484 | 32 of 244 | 728 | NCT02655016 | Trial comparisons |
| Trabectedin/DOXIL vs DOXIL: serious adverse events | 133 of 333 | 102 of 330 | 663 | NCT00113607 | Trial comparisons |
| Pembrolizumab + Paclitaxel ± Bevacizumab vs Placebo + Paclitaxel ± Bevacizumab: deaths from any cause | 225 of 322 | 244 of 321 | 643 | NCT05116189 | Trial comparisons |
| Pembrolizumab + Paclitaxel ± Bevacizumab vs Placebo + Paclitaxel ± Bevacizumab: serious adverse events | 178 of 320 | 122 of 318 | 638 | NCT05116189 | Trial comparisons |
| Rucaparib 600 mg Tablets vs Placebo Tablets: deaths from any cause | 9 of 372 | 2 of 189 | 561 | NCT01968213 | Trial comparisons |
| Rucaparib 600 mg Tablets vs Placebo Tablets: serious adverse events | 91 of 372 | 20 of 189 | 561 | NCT01968213 | Trial comparisons |
| Paclitaxel + Carboplatin Followed 4 Weeks Later by Paclitaxel vs Paclitaxel + Carboplatin Followed by Observation: Overall Survival | 44 of 274 | 53 of 268 | 542 | NCT00003644 | Trial comparisons |
| Paclitaxel + Carboplatin Followed 4 Weeks Later by Paclitaxel vs Paclitaxel + Carboplatin Followed by Observation: deaths from any cause | 44 of 274 | 53 of 268 | 542 | NCT00003644 | Trial comparisons |
| Paclitaxel + Carboplatin Followed 4 Weeks Later by Paclitaxel vs Paclitaxel + Carboplatin Followed by Observation: serious adverse events | 7 of 274 | 5 of 268 | 542 | NCT00003644 | Trial comparisons |
| Part 1 Overall vs Part 2 Overall: deaths from any cause | 2 of 204 | 18 of 287 | 491 | NCT01891344 | Trial comparisons |
| Part 1 Overall vs Part 2 Overall: serious adverse events | 54 of 204 | 92 of 287 | 491 | NCT01891344 | Trial comparisons |
| Mirvetuximab Soravtansine vs Investigator's Choice (IC) Chemotherapy: deaths from any cause | 162 of 227 | 177 of 226 | 453 | NCT04209855 | Trial comparisons |
| Mirvetuximab Soravtansine vs Investigator's Choice (IC) Chemotherapy: serious adverse events | 62 of 227 | 73 of 226 | 453 | NCT04209855 | Trial comparisons |
| Lurbinectedin vs Control (PLD or Topotecan): deaths from any cause | 170 of 219 | 171 of 213 | 432 | NCT02421588 | Trial comparisons |
| Lurbinectedin vs Control (PLD or Topotecan): serious adverse events | 92 of 219 | 85 of 213 | 432 | NCT02421588 | Trial comparisons |
| Mirvetuximab Soravtansine vs Investigator's Choice (IC) Chemotherapy: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 211 of 218 | 194 of 207 | 425 | NCT04209855 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0008170/comparisons